Colon Pharmaceuticals (002422.SZ) announced that its holding subsidiary, Sichuan Collenbotai Biomedical Co., Ltd. (“Colunbotai”), will announce its anti-TROP2 ADC lucansatuzumab (sAC-TMT) (formerly SKB264/) at the 2024 American Association for Cancer Research (AACR) Annual Meeting to be held in San Diego, California, USA from April 5 to 10, 2024, at the poster presentation session from 1:30 p.m. to 5:00 p.m. local time on April 9, 2024 CT247 MK-2870) The latest efficacy and safety results of the Phase 2 study for previously treated patients with advanced non-small cell lung cancer (NSCLC), and the preliminary efficacy and safety results of the phase 2 study of its anti-TROP2 ADC lucan satuzumab (Sac-TMT) for patients with advanced gastric cancer or esophagogastric junction (GEJ) cancer were announced in the form of an oral report from 2:30 p.m. to 4:30 p.m. local time (Summary Report No.: CT038).